Identity
Gilead Sciences, S.L.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €76.2M | |
| 2025 | €256.8M | |
| 2024 | €122.3M | |
| + regional platforms | ||
| 2023 | €55.7M | |
| 2022 | €26.6M | |
| 2021 | €75.1M | |
| 2020 | €35.7M | |
| 2019 | €60.1M | |
| 2018 | €7.0M | |
| 2017 | €10.8M | |
| 2016 | €10.0M | |
In figures
Volume
Between 2016 and 2026 it won 878 contracts worth €736M on its own, with 47 buyers. Its 7 joint-venture (UTE) contracts are shown separately.
Price
It has fewer than 3 comparable awards, too few to compute its median discount.
Competition
Since 2024, 0% of its comparable value was won with a discount and against other bidders. It was the only bidder in 96% of its contracts (2016–2026).
Renewals
54 contracts (€59.3M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Gilead Sciences, S.L.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Gilead Sciences, S.L.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
Only 1 contested award can be compared — not enough to read how it prices. Of its 878 contracts, 638 are call-offs under framework agreements and 128 were awarded without competition (negotiated without publicity or direct award).
Framework call-offs 638 · Single bidder 11 · Non-competitive procedure 128 · No comparable budget 100 · Contested, comparable 1
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
How it wins
Whether it wins with or without competition.
97% of the comparable value since 2024 (€4.15M of €4.27M) was won at the tender price and without other bidders. Only €118k (3%) was awarded with a discount and without other bidders.
Comparable: 9 awards with a published budget and bidder count (€4.27M of €455M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 73.1% of the value was awarded through negotiated without publicity procedure (51.5% of contracts); followed by Based on a framework agreement (10.9%) and Other (9.9%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 54 of its contracts come up for tender again, worth €59.3M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €474k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €42.4k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €31.1k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €23.3k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €6.82k |
and 49 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Gerencia de Servicio Sanitarios de Fuerteventura | 346 | 117 M | 2019–2026 |
| Servicio Andaluz de Salud | 112 | 101 M | 2024–2026 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 17 | 101 M | 2024–2026 |
| Subdirección General de Planificación y Gestión Económica | 95 | 52 M | 2017–2026 |
| Fundació de Gestió Sanitària de l'Hospital de la Santa Creu i Sant Pau | 4 | 36 M | 2021–2024 |
and 42 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 811 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 07/09/2026 | Suministro de Axicabtagen Ciloleucel. "Emergencia". | Servicio Cántabro de Salud | 1 | — |
| 13/08/2026 | Suministro de Axicabtagen Ciloleucel. "Emergencia". | Servicio Cántabro de Salud | 1 | — |
| 10/07/2026 | Suministro de Axicabtagen Ciloleucel. "Emergencia". | Servicio Cántabro de Salud | 1 | — |
| 01/07/2026 | Suministro de Axicabtagen Ciloleucel. "Emergencia". | Servicio Cántabro de Salud | 1 | — |
| 08/06/2026 | cpca 1º cbam gilead sciences, s.l. exp. 578/2025 suministro medicamentos exclusivos, cca: +6.i+e9q8… | Servicio Andaluz de Salud | 1 | €1.85M |